IPIAD: an augmentation to standard treatment of PDAC using five repurposed drugs
2024-02-09
(Press-News.org)
“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).”
BUFFALO, NY- February 9, 2024 – A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.”
In this new paper, researcher Richard E. Kast from IIAIGC Study Center presents the data and rationale for adding five generic non-oncology drugs from general medical practice to gemcitabine, nab-paclitaxel, a current standard cytotoxic chemotherapy of pancreatic ductal adenocarcinoma. The regimen, called IPIAD, uses an angiotensin receptor blocker (ARB) irbesartan indicated for treating hypertension, an old antimicrobial drug pyrimethamine indicated for treating toxoplasmosis or malaria, an old antifungal drug itraconazole, an old broad spectrum antibiotic azithromycin, and an old antibiotic dapsone.
“In reviewing selected growth driving systems active in pancreatic ductal adenocarcinoma then comparing these with detailed data on ancillary attributes of the IPIAD drugs, one can predict clinical benefit and slowing growth of pancreatic ductal adenocarcinoma by this augmentation regimen.”
Read the full paper: DOI: https://doi.org/10.18632/oncoscience.594
Correspondence to: Richard E. Kast
Email: richarderickast@gmail.com
Keywords: gemcitabine, multidrug, paclitaxel, pancreatic ductal adenocarcinoma, repurposed
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
X, formerly known as Twitter
Instagram
Facebook
YouTube
LinkedIn
For media inquiries, please contact media@impactjournals.com.
Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2024-02-09
SAN ANTONIO, Feb. 9, 2024 – The UT Health San Antonio School of Dentistry has opened a special-care dental clinic, the first of its kind in an academic setting in South Texas that will serve people of all ages with intellectual, developmental, cognitive or physical disabilities.
With spacious, specially designed treatment rooms featuring adjustable sound and lighting and even a “Zen Den” multi-sensory room to help reduce anxiety, the Phil and Karen Hunke Special Care Clinic occupies approximately ...
2024-02-09
MIT engineers have developed a small ultrasound sticker that can monitor the stiffness of organs deep inside the body. The sticker, about the size of a postage stamp, can be worn on the skin and is designed to pick up on signs of disease, such as liver and kidney failure and the progression of solid tumors.
In an open-access study that will appear in Science Advances, the team reports that the sensor can send sound waves through the skin and into the body, where the waves reflect off internal organs and back out to the sticker. The pattern of the reflected waves can be read as ...
2024-02-09
New Haven, Conn. — A Yale-led research team has picked a side in the “Snowball Earth” debate over the possible cause of planet-wide deep freeze events that occurred in the distant past.
According to a new study, these so-called “Snowball” Earth periods, in which the planet’s surface was covered in ice for thousands or even millions of years, could have been triggered abruptly by large asteroids that slammed into the Earth.
The findings, detailed in the journal Science Advances, may answer a question ...
2024-02-09
Researchers have developed a sensor made from ‘frozen smoke’ that uses artificial intelligence techniques to detect formaldehyde in real time at concentrations as low as eight parts per billion, far beyond the sensitivity of most indoor air quality sensors.
The researchers, from the University of Cambridge, developed sensors made from highly porous materials known as aerogels. By precisely engineering the shape of the holes in the aerogels, the sensors were able to detect the fingerprint of formaldehyde, a common indoor air pollutant, at room temperature.
The proof-of-concept sensors, which require minimal power, could be adapted to detect ...
2024-02-09
CLEVELAND—University Hospitals (UH) Brain Health & Memory Center is now treating patients with LEQEMBI® (lecanemab), a Food and Drug Administration-approved medication for the treatment of Alzheimer’s disease.
“Those with Alzheimer’s disease often have an abnormal buildup of plaques in their brain that contain a protein called beta-amyloid,” said Charles J. Duffy, MD, PhD, neurologist and Director of the Brain Health & Memory Center within the UH Neurological Institute. “Lecanemab ...
2024-02-09
Using single photons as qubits has become a prominent strategy in quantum information technology. Accurately determining the number of photons is crucial in various quantum systems, including quantum computation, quantum communication, and quantum metrology. Photon-number-resolving detectors (PNRDs) play a vital role in achieving this accuracy and have two main performance indicators: resolving fidelity, which measures the probability of accurately recording the number of incident photons, and dynamic range, which describes the maximum resolvable photon number.
Superconducting nanostrip single-photon detectors (SNSPDs) are considered the leading ...
2024-02-09
DURHAM, N.C. -- It might look like a comet or a shooting star, but this time-lapse video is actually a tiny plant root, not much thicker than a human hair, magnified hundreds of times as it grows under the microscope.
Researchers at Duke University have been making such movies by peering at stem cells near the root’s tip and taking snapshots as they divide and multiply over time, using a technique called light sheet microscopy.
The work offers more than a front row seat to the drama of growing roots. By watching how the cells divide in response to certain chemical signals, the team is finding new clues to how stem cells choose one ...
2024-02-09
LEXINGTON, Ky. (Feb. 8, 2024) — A researcher in the University of Kentucky College of Nursing has been selected as a scholar for the Environmental Health Research Institute for Nurse and Clinician Scientists (EHRI-NCS).
EHRI-NCS is a year-long flipped classroom, train-the-trainer and mentorship program aimed at developing a new era of environmental health nursing science. It’s led by Castner Incorporated, a health research company, in partnership with Emory University, Washington State University and University of Alabama in Huntsville.
Stacy Stanifer, Ph.D., an advanced practice registered nurse and an assistant professor of nursing, was selected to participate. ...
2024-02-09
CHAPEL HILL, N.C. – UNC School of Medicine researcher Sarah Cohen, PhD, and Ian Windham, a former PhD student from the Cohen lab, have made a new discovery about apolipoprotein E (APOE) – the biggest genetic risk factor for late-onset Alzheimer’s disease.
Older people who inherited a genetic variant called APOE4 from their parents have a two- or three-times greater risk of developing the late-onset neurodegenerative disease. If researchers can better understand how APOE4 is affecting brain cells, it may help them design effective therapeutics and target the mechanisms causing the enhanced disease risk.
Cohen and Windham performed an exceptionally ...
2024-02-09
In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and programmed by means of genetic engineering to detect proteins on the malignant tumour cells. Back in the body, the CAR T cells then fight the cancer cells. Due to some heavy side effects, this therapy requires extreme caution and long hospital stays. Scientists at University Hospital Cologne are therefore researching ...
LAST 30 PRESS RELEASES:
[Press-News.org] IPIAD: an augmentation to standard treatment of PDAC using five repurposed drugs
